Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Yahoo! Finance
attributed to the launch of upcoming therapies such as Olpasiran (AMG 890) (Amgen/Arrowhead Pharmaceuticals), Obicetrapib (TA-8995) (Newamsterdam Pharma/Menarini), Apabetalone (RVX000222) (Resverlogix), Pelacarsen (TQJ230) (Ionis Pharmaceuticals/Novartis), and others, and the increasing prevalence of ASCVD. New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as Olpasiran (AMG 890) (Amgen/Arrowhead Pharmaceuticals), Obicetrapib (TA-8995) (Newamsterdam Pharma/Menarini), Apabetalone (RVX000222) (Resverlogix), Pelacarsen (TQJ230) (Ionis Pharmaceuticals/Novartis), and others, and the increasing prevalence of ASCVD. DelveInsight's Atherosclerotic Ca
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic PrioritiesGlobeNewswire
- NewAmsterdam Pharma (NASDAQ:NAMS) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $50.00. They now have a "buy" rating on the stock.MarketBeat
- Is It Too Late To Consider NewAmsterdam Pharma After Its Strong 2025 Share Price Rally? [Yahoo! Finance]Yahoo! Finance
NAMS
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- NAMS's page on the SEC website